Chronic Kidney Disease Drugs is fastest growing segment fueling the growth of Chronic Kidney Disease Market

 

Chronic Kidney Disease (CKD) Drugs treat CKD to delay its progression by controlling other associated conditions like high blood pressure and diabetes. CKD Drugs are essential in managing the symptoms and slowing the progression of renal damage. Some key advantages include controlling complications, maintaining fluid and mineral balance and improving quality of life.

The global Chronic Kidney Disease market offers drugs for various stages of CKD which aim to control complications, delay progression and improve quality of life. Key drug classes include ACE Inhibitors, angiotensin II receptor blockers, diuretics, calcium channel blockers, erythropoiesis-stimulating agents (ESAs) and phosphate binders.

The global Chronic Kidney Disease Drugs Market is estimated to be valued at US$ 13,220.0 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the key trends in the Chronic Kidney Disease Drugs Market is the focus on developing novel drug molecules for end-stage renal disease patients. Several pharmaceutical companies are conducting clinical trials for new and advanced CKD drugs with better safety, efficacy and extended renal protection. For instance, trials are being conducted for drugs targeting metabolic acidosis, hypoalbuminemia, hyperphosphatemia and delayed graft function post-kidney transplant. Such novel drug innovations are anticipated to positively impact the Chronic Kidney Disease Drugs Market growth over the forecast period.
Segment Analysis
The global chronic kidney disease drugs market is segmented into product, route of administration, distribution channel, and end user. Based on product, the market is categorized into calcium channel blockers, antihypertensive drugs, erythropoietin stimulating agents, beta blockers, diuretics, and ACE inhibitors. Among these, ACE inhibitors dominate the market as they are widely used as first-line treatment for chronic kidney disease. They help lower blood pressure and slow the progression of kidney damage.

Key Takeaways
The global chronic kidney disease drugs market is expected to witness high growth, exhibiting a CAGR of 4.5% over the forecast period, due to the increasing prevalence of diabetes, hypertension, and cardiovascular diseases.

Regional analysis: North America accounts for the largest share in the global market owing to the rising prevalence of chronic kidney disease and increasing healthcare expenditure. Asia Pacific is expected to grow at the highest CAGR during the forecast period due to the increasing geriatric population, growing awareness about kidney diseases, and improving healthcare infrastructure in emerging countries.

Key players: Key players operating in the chronic kidney disease drugs market are Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.

Comments

Post a Comment

Popular posts from this blog

Unveiling Health Secrets: Exploring the Potential of Blood-Based Biomarkers

Image
  The human body is a complex and intricate system, often harboring subtle signs of its inner workings. One of the most promising avenues for unlocking these secrets lies within our bloodstream – a treasure trove of information encoded in the form of blood-based biomarkers. These biomarkers, measurable indicators present in the blood, hold the potential to revolutionize healthcare by providing early detection, accurate diagnosis, and personalized treatment approaches. Blood-based biomarkers encompass a wide range of molecules – from proteins and nucleic acids to metabolites and even circulating cells. Researchers have been diligently working to identify specific biomarkers associated with various diseases and conditions. For instance, elevated levels of certain proteins might point to cardiovascular diseases, while specific genetic material could indicate the presence of cancer. By analyzing these biomarkers, clinicians gain valuable insights into an individual's health status, en...
Read more

Revolutionizing Biology: Advancements in Single Cell Analysis Techniques

Image
  Single cell analysis has emerged as a groundbreaking technology that is revolutionizing the field of biology. Traditionally, biological studies were conducted on populations of cells, averaging out the heterogeneity present within them. However, the advent of single cell analysis has enabled scientists to delve into the complexity of individual cells, uncovering a wealth of previously inaccessible information. Advancements in single cell analysis techniques have paved the way for a deeper understanding of cellular heterogeneity, gene expression, and cellular behavior. One of the most remarkable techniques is single-cell RNA sequencing (scRNA-seq), which allows scientists to measure gene expression in individual cells. This breakthrough has led to the identification of rare cell types, understanding of cellular communication networks, and the discovery of novel biomarkers. Moreover, single cell imaging techniques, such as single cell fluorescence microscopy, have enabled research...
Read more

Medical Robots Market Poised to Grow Owing to Improving Healthcare Infrastructure

Image
 The Medical Robots Market is anticipated to witness robust growth due to rising healthcare spending across the globe. Medical robots are used to perform minimal invasive surgeries with greater accuracy and flexibility. Growing preference for Robot-Assisted Surgery (RAS) over conventional open surgeries due to benefits such as shorter recovery time and minimum operative scars has been augmenting demand for medical robots. Key functions include guiding and positioning surgical accessories like guide tubes in radiology and guiding catheter and wires in cardiology. With rising chronic disease prevalence associated with aging populations, the need for more surgical procedures is surging which requires precise action minimally invasive robotic systems can provide. The Global Medical Robots Market is estimated to be valued at US$ 11.47 Bn in 2024 and is expected to exhibit a CAGR of 16% over the forecast period 2023 to 2030. Key Takeaways: Key players operating in the Medical Robo...
Read more